Pharmasyntez to Help Skolkovo Resident Commercialize Drug Against Leukemia
Fusion Pharma, a resident of the Skolkovo Foundation's Biomedical Technologies Cluster, signed a
license agreement with Pharmasyntez to commercialize an innovative
antileukemic
drug. The licencing deal implies an upfront payment, milestones and...
Zur Pressemeldung auf sk.ru